vs
EXACT SCIENCES CORP（EXAS）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），EXACT SCIENCES CORP同比增速更快（23.1% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -6.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
EXAS vs RHI — 直观对比
营收规模更大
RHI
是对方的1.5倍
$878.4M
营收增速更快
EXAS
高出28.9%
-5.8%
自由现金流更多
RHI
多$50.3M
$120.4M
两年增速更快
EXAS
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | — |
| 毛利率 | 70.1% | 37.6% |
| 营业利润率 | -9.4% | 1.7% |
| 净利率 | -9.8% | — |
| 营收同比 | 23.1% | -5.8% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRHI
| Q4 25 | $878.4M | $1.3B | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.4B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.4B | ||
| Q3 24 | $708.7M | $1.5B | ||
| Q2 24 | $699.3M | $1.5B | ||
| Q1 24 | $637.5M | $1.5B |
净利润EXASRHI
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $42.9M | ||
| Q2 25 | $-1.2M | $41.0M | ||
| Q1 25 | $-101.2M | $17.4M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $65.5M | ||
| Q2 24 | $-15.8M | $68.2M | ||
| Q1 24 | $-110.2M | $63.7M |
毛利率EXASRHI
| Q4 25 | 70.1% | 37.6% | ||
| Q3 25 | 68.6% | 37.2% | ||
| Q2 25 | 69.3% | 37.2% | ||
| Q1 25 | 70.8% | 36.9% | ||
| Q4 24 | 69.0% | 38.8% | ||
| Q3 24 | 69.4% | 39.0% | ||
| Q2 24 | 69.8% | 39.2% | ||
| Q1 24 | 70.0% | 38.1% |
营业利润率EXASRHI
| Q4 25 | -9.4% | 1.7% | ||
| Q3 25 | -3.0% | 1.0% | ||
| Q2 25 | -0.3% | 0.1% | ||
| Q1 25 | -13.6% | 2.9% | ||
| Q4 24 | -122.8% | 4.7% | ||
| Q3 24 | -5.6% | 4.1% | ||
| Q2 24 | -3.8% | 5.1% | ||
| Q1 24 | -16.7% | 2.8% |
净利率EXASRHI
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 3.2% | ||
| Q2 25 | -0.1% | 3.0% | ||
| Q1 25 | -14.3% | 1.3% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 4.5% | ||
| Q2 24 | -2.3% | 4.6% | ||
| Q1 24 | -17.3% | 4.3% |
每股收益（稀释后）EXASRHI
| Q4 25 | $-0.45 | $0.32 | ||
| Q3 25 | $-0.10 | $0.43 | ||
| Q2 25 | $-0.01 | $0.41 | ||
| Q1 25 | $-0.54 | $0.17 | ||
| Q4 24 | $-4.69 | $0.53 | ||
| Q3 24 | $-0.21 | $0.64 | ||
| Q2 24 | $-0.09 | $0.66 | ||
| Q1 24 | $-0.60 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.3B |
| 总资产 | $5.9B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASRHI
| Q4 25 | $964.7M | $464.4M | ||
| Q3 25 | $1.0B | $365.3M | ||
| Q2 25 | $858.4M | $380.5M | ||
| Q1 25 | $786.2M | $342.5M | ||
| Q4 24 | $1.0B | $537.6M | ||
| Q3 24 | $1.0B | $570.5M | ||
| Q2 24 | $946.8M | $547.4M | ||
| Q1 24 | $652.1M | $540.9M |
股东权益EXASRHI
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $3.2B | $1.5B | ||
| Q2 24 | $3.2B | $1.5B | ||
| Q1 24 | $3.1B | $1.5B |
总资产EXASRHI
| Q4 25 | $5.9B | $2.9B | ||
| Q3 25 | $5.9B | $2.8B | ||
| Q2 25 | $5.8B | $2.8B | ||
| Q1 25 | $5.7B | $2.7B | ||
| Q4 24 | $5.9B | $2.9B | ||
| Q3 24 | $6.7B | $3.0B | ||
| Q2 24 | $6.7B | $2.9B | ||
| Q1 24 | $6.4B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $170.8M |
| 自由现金流率自由现金流/营收 | 13.7% | 13.1% |
| 资本支出强度资本支出/营收 | 3.6% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $266.8M |
8季度趋势，按日历期对齐
经营现金流EXASRHI
| Q4 25 | $151.7M | $182.5M | ||
| Q3 25 | $219.9M | $77.4M | ||
| Q2 25 | $89.0M | $119.4M | ||
| Q1 25 | $30.8M | $-59.3M | ||
| Q4 24 | $47.1M | $154.8M | ||
| Q3 24 | $138.7M | $129.6M | ||
| Q2 24 | $107.1M | $142.0M | ||
| Q1 24 | $-82.3M | $-15.9M |
自由现金流EXASRHI
| Q4 25 | $120.4M | $170.8M | ||
| Q3 25 | $190.0M | $63.6M | ||
| Q2 25 | $46.7M | $104.2M | ||
| Q1 25 | $-365.0K | $-71.7M | ||
| Q4 24 | $10.7M | $140.5M | ||
| Q3 24 | $112.6M | $111.8M | ||
| Q2 24 | $71.2M | $129.6M | ||
| Q1 24 | $-120.0M | $-27.7M |
自由现金流率EXASRHI
| Q4 25 | 13.7% | 13.1% | ||
| Q3 25 | 22.3% | 4.7% | ||
| Q2 25 | 5.8% | 7.6% | ||
| Q1 25 | -0.1% | -5.3% | ||
| Q4 24 | 1.5% | 10.2% | ||
| Q3 24 | 15.9% | 7.6% | ||
| Q2 24 | 10.2% | 8.8% | ||
| Q1 24 | -18.8% | -1.9% |
资本支出强度EXASRHI
| Q4 25 | 3.6% | 0.9% | ||
| Q3 25 | 3.5% | 1.0% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 4.4% | 0.9% | ||
| Q4 24 | 5.1% | 1.0% | ||
| Q3 24 | 3.7% | 1.2% | ||
| Q2 24 | 5.1% | 0.8% | ||
| Q1 24 | 5.9% | 0.8% |
现金转化率EXASRHI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.08× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
